VBC101

VBC101 is a novel bispecific antibody-drug conjugate designed for the treatment of advanced solid tumors. Developed by VelaVigo, it targets both Epidermal Growth Factor Receptor (EGFR) and c-Met, two important oncogenic drivers frequently overexpressed in solid tumors. VBC101 functions as a mitosis inhibitor, most likely through an auristatin toxin payload conjugated to the bispecific antibody backbone. It acts by binding to and inhibiting EGFR and c-Met, leading to targeted cytotoxicity in cancer cells expressing these antigens. The drug is currently in preclinical and early clinical development, with a first-in-human Phase 1/2a clinical trial planned for advanced solid tumor malignancies[1][2][3][5].